<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="?"><plain>How to use oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> fixed-dose combination tablet for the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to diet and exercise, the majority of diabetic patients need drug therapy to achieve optimal glycemic control </plain></SENT>
<SENT sid="2" pm="."><plain>Monotherapy with oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent is the firstline pharmacologic treatment option </plain></SENT>
<SENT sid="3" pm="."><plain>However, in order to maintain glycemic control, additional oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents are often added to monotherapies resulting in dual therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Dual therapy can be prescribed as separate pills, or as a single pill containing two agents </plain></SENT>
<SENT sid="5" pm="."><plain>Randomized controlled trials of patients requiring dual therapy, have shown fixed-dose combination therapies to have superior efficacy when compared to loose-pills combination therapies </plain></SENT>
<SENT sid="6" pm="."><plain>T2DM patients treated with fixed-dose combination therapies may have better adherence, improved satisfaction, and lower direct costs, compared to those treated with loose-pill combination therapies </plain></SENT>
</text></document>